Undisclosed PSMAxCD3 T-cell engager / AbCellera - LARVOL DELTA

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025 (Businesswire) - "AbCellera...announced an upcoming poster presentation that includes preclinical in vivo data on its PSMA x CD3 T-cell engagers at the American Association for Cancer Research (AACR) 116th Annual Meeting..."

Preclinical • Prostate Cancer

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024 (Businesswire) - "AbCellera...announced new data on its T-cell engager (TCE) programs at the American Association for Cancer Research (AACR) Annual Meeting 2024 at the San Diego Convention Center, with three posters being presented on April 8 and one on April 9....Data show how AbCellera is expanding the reach of T-cell engagers with: CD3-binding antibodies that consistently generate T-cell engagers with potent tumor-cell killing and low cytokine release across multiple tumor targets, including PSMA, B7-H4, and 5T4; Costimulatory CD28-binding antibodies that stimulate T cells without superagonist activity; Highly specific T-cell engagers for the peptide-MHC target MAGE-A4."

Preclinical • Oncology

AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024 (Businesswire) - "AbCellera will present four posters at AACR that demonstrate how it is leveraging its platform to develop T-cell engagers with potent tumor-cell killing and low cytokine release for multiple cancer targets. Using data integrated from across these programs, AbCellera will present new insights into T-cell engager function. In addition, AbCellera will present data on novel CD28-binding antibodies that can be used to optimize T-cell engagers, particularly for solid tumors that are difficult to treat using current immunotherapies."

Preclinical • Oncology